The in vivo appearance of soluble interleukin (IL)-6 receptor (sIL-
Interleukin (IL)-6 is a pleiotropic cytokine with central roles in the regulation of inflammatory and immune reactions.' 2 Recently we3 4 and other groups5A8 described the kinetics of the appearance of IL-6 in blood and tissue from patients with inflammatory bowel disease, and have suggested that IL-6 is related to the pathophysiology of this disease.
Since IL-6 responses are mediated by specific membrane receptors on target cells, [9] [10] [11] the IL-6 receptor could be very important in modulating the actions of IL-6 in vivo, especially where immunopathogenesis is associated with IL-6. The IL-6 receptor (R) system is composed of two functionally different chains: an 80 kDa ligand binding chain, known as IL-6R, and a 130 kDa non-ligand binding but signal transducing chain, gpl30.'2 gp130 is associated with complexes of IL-6 and IL-6R, resulting in the formation of high affinity IL-6 binding sites and transduction of the signal. A soluble form of IL-6R with a molecular weight of 50-55 kDa was recently found in human serum and urine.13 14 Furthermore, genetically engineered soluble (s) IL-6R could associate with gpl30 on the cell surface in the presence of IL-6, and this molecule lacking transmembrane and cytoplasmic domains could also transduce the IL-6 signal.1' These findings suggest that sIL-6R plays an important role as a naturally occurring enhancer of IL-6 action in vivo. However, little is known about the profile of sIL-6R in human diseases. ' After washing again, substrate solution (1 mg/ml of o-phenylenediamine, 0.03% H202 in 0.1 M citrate phosphate buffer, pH 5 0) was added. The plates were incubated for 10 minutes and the reaction was terminated with 100 pA1/well of 1 N H2S04 solution. The absorbance was then measured at 492 nm/ 630 nm. Purified sIL-6R from the supernatant of CHO-CN cells'9 was used as a reference reagent. Intra-assay and interassay replicates gave results with coefficients ofvariation of less than 3.5% and 4.8%, respectively. The mean (SEM) recovery of sIL-6R from serum was 97.3 (1.7)%. Sample titration gave detectable levels of sIL-6R that always followed the standard curve.
DETERMINATION OF IL-6 AND OTHER LABORATORY PARAMETERS ELISA methods were used to assay IL-6 (SRL Inc, Tokyo, Japan)34 and sIL-2R (Immunotech SA, France). C-reactive protein was measured by laser nephelometry (NA Latex CRP kit, Hoechst Japan, Tokyo, Japan). Levels of immunoglobulins were quantitated by radial immunodiffusion. Total leukocyte counts, platelet counts, erythrocyte sedimentation rates, serum total protein levels, and protein electrophoresis profiles were determined according to established techniques.
GEL FILTRATION ANALYSIS
Chromatographic procedures were carried out on a fast protein liquid chromatography (FPLC) system (Pharmacia, Sweden). Each serum sample was fractionated by gel filtration through a Superose 6 HR 10/30 column equilibrated with 20 mM phosphate buffer, pH 7'5, and 50 mM NaCl. Each sample (90 pAl) was eluted with a buffer flow rate of 0.3 ml/min. Fractions of 0-6 ml were collected and immunoreactive IL-6 and sIL-6R levels in each fraction were measured by ELISA. Also, ot2-macroglobulin levels in these fractions were determined by laser nephelometry (BehringWerke AG. Marburo. Germanv). The column z~~~~~~~~~~~~~~~~~~~~~~~" -- Figure 3 shows the representative elution profiles of IL-6 and sIL-6R immunoreactivities in sera from patients with active ulcerative colitis and Crohn's disease. Two major peaks and some minor peaks of IL-6 immunoreactivity were seen consistently: one major peak was eluted in fractions corresponding to 25-35 kDa, whereas another peak was found at 150 kDa. Furthermore, a single immunoreactive sIL-6R peak was identified that seemed to elute together with the 150 kDa IL-6 peak. There was, however, only a minor or no peak corresponding to IL-6 that coeluted with ox2-macroglobulin.
To confirm the in vivo presence of the IL-6-sIL-6R complex, we developed a specific LS-ELISA. As shown in Figure 4, 
